Identifying what is the biological driver of the individual tumour can be of great help (i.e., whether ER or HER2 signalling is dominating and driving the growth and progression of the tumour), though pathway interaction and crosstalk can cause the cancer to change course throughout treatment. Here, ERBB2 is linked to neoplasm.